MedTrace Logo

AZD7451 for Recurrent Gliomas

NCT01468324 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-12-17

No results posted yet for this study

Summary

Background:

\- AZD7451 is a drug that may help interfere with brain tumor cell growth. It can prevent glioma cells from entering into normal brain tissue, and slow or stop the growth of additional tumors. Researchers want to see if AZD7451 is effective against gliomas that have not responded to surgery, radiation, or chemotherapy.

Objectives:

\- To see if AZD7451 is a safe and effective treatment for gliomas that have not responded to standard treatments.

Eligibility:

\- Individuals at least 18 years of age who have gliomas that have not responded to standard treatments.

Design:

* Participants will be screened with a physical exam, medical history, blood and urine tests, heart function tests, an eye exam, and imaging studies.
* Participants will take AZD7451 daily by mouth for 28-day cycles of treatment.
* Participants will keep a medication diary and record any side effects. Treatment will be monitored with frequent blood tests and imaging studies.
* Treatment will continue as long as there are no serious side effects and the tumor does not start growing again....

Conditions

Interventions

DRUG

AZD7451

Depending on dose level, AZD7451 will be given once daily for 28 day cycles.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Teri N Kreisl, M.D. · National Cancer Institute (NCI)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-05
Primary Completion
2014-04-23
Completion
2014-04-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01468324 on ClinicalTrials.gov